Search Results for keywords:"National Cancer Institute"

The National Cancer Institute has announced a closed meeting to take place on May 9, 2025. This meeting, part of the Federal Advisory Committee Act, will review and evaluate contract proposals and will be held virtually. Confidentiality will be maintained to protect sensitive trade secrets and personal privacy. The session will run from 9:00 a.m. to 6:00 p.m., and any inquiries can be directed to Shamala K. Srinivas, Ph.D.

The National Cancer Institute, part of the National Institutes of Health, is considering granting an exclusive patent license to Kyverna Therapeutics for technology involving chimeric antigen receptors (CARs) that target the CD19 protein. This technology is aimed at creating a treatment for autoimmune diseases using a patient’s own altered T lymphocytes. The license could cover worldwide territories and would allow Kyverna to develop, produce, and market this therapy. Public comments or objections about the patent license need to be submitted by March 5, 2021.

The National Cancer Institute announced that it will hold two closed meetings in March 2025 to discuss and evaluate grant applications. The meetings will not be open to the public because they might involve discussing confidential information like trade secrets and personal data. Both meetings will be held virtually from the National Cancer Institute in Rockville, Maryland. The meetings aim to focus on different aspects of cancer research, including clinical and translational research, and biospecimen science approaches.

The National Institutes of Health (NIH) is seeking approval from the Office of Management and Budget (OMB) for information collection related to the Cancer Therapy Evaluation Program (CTEP) and the Division of Cancer Prevention (DCP) under the National Cancer Institute (NCI). This information is crucial for managing clinical trials in cancer research, ensuring compliance with federal regulations, and improving processes. The request is part of the requirements of the Paperwork Reduction Act of 1995, and public comments are invited within 30 days of publication. There are no costs to respondents apart from their time, and the estimated annual burden is 151,792 hours.

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS), is planning to grant an exclusive license to StraightLine Bio, Inc. for certain anti-cancer inventions. These inventions involve patents related to T cell receptors targeting a cancer antigen called KK-LC-1, which is found in certain epithelial cancers. The proposed license would allow StraightLine Bio to develop and commercialize therapies using this technology worldwide, but with some specific exclusions. The public has a chance to comment or object to this plan until December 26, 2024.

The National Cancer Institute has announced several closed meetings in accordance with the Federal Advisory Committee Act. These meetings will not be open to the public to protect sensitive information like trade secrets and personal details of individuals involved in grant applications and contract proposals. Notable meetings include sessions to evaluate contract proposals and grant applications relating to cancer research, occurring throughout March 2021. For more information, individuals can contact the Scientific Review Officers listed in the notice.

The National Cancer Institute has announced upcoming meetings focused on reviewing and evaluating grant applications, set to take place virtually on April 10-11, 2025. These meetings will be closed to the public to protect confidential information and personal privacy. They involve the National Cancer Institute Special Emphasis Panel, which aims to explore innovative technologies for cancer research. Interested parties can contact Jeffrey E. DeClue, the Scientific Review Officer, for further information.

The National Cancer Institute has announced a change to the meeting date for the Special Emphasis Panel, initially scheduled for March 4, 2025. The meeting is now set for March 3, 2025, but the time and location remain the same, from 11:00 a.m. to 4:00 p.m. at the National Cancer Institute in Rockville, Maryland. The meeting will be conducted virtually and is closed to the public.

The National Cancer Institute, part of the National Institutes of Health, announced a series of closed virtual meetings in June 2025. These meetings, held by special emphasis panels, are intended to review and evaluate grant applications related to cancer research. They will be closed to the public to protect confidential information and personal privacy. Meeting details, including dates, times, and contact information for scientific review officers, are provided for each committee session.

The National Cancer Institute announced several upcoming closed meetings to review grant applications and contract proposals. These meetings will not be open to the public to protect confidential information and personal privacy. Each meeting is led by a Scientific Review Officer, and the topics include reviews for SBIR contracts, clinical and translational research, and various other cancer research initiatives. The meetings will take place via telephone conference calls from late February through early April 2021.